Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19

A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with CoronaVirus disease-19 (COVID-19). Accordingly, recent data suggested a beneficial role of low molecular weight heparin (LMWH), but the optimal dosage of this treatment is unknown. We evaluated the associat...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Thromb Thrombolysis
Κύριοι συγγραφείς: Mennuni, Marco G., Renda, Giulia, Grisafi, Leonardo, Rognoni, Andrea, Colombo, Crizia, Lio, Veronica, Foglietta, Melissa, Petrilli, Ivan, Pirisi, Mario, Spinoni, Enrico, Azzolina, Danila, Hayden, Eyal, Aimaretti, Gianluca, Avanzi, Gian Carlo, Bellan, Mattia, Cantaluppi, Vincenzo, Capponi, Andrea, Castello, Luigi M., D’Ardes, Damiano, Corte, Francesco Della, Gallina, Sabina, Krengli, Marco, Malerba, Mario, Pierdomenico, Sante D., Savoia, Paola, Zeppegno, Patrizia, Sainaghi, Pier P., Cipollone, Francesco, Patti, Giuseppe
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Springer US 2021
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7919624/
https://ncbi.nlm.nih.gov/pubmed/33649979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11239-021-02401-x
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια